| Name | Title | Contact Details |
|---|
B&W Handicap Equipment is a Fayetteville, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
One of the nation’s leading academic medical centers, Robert Wood Johnson University Hospital provides state-of-the-art care across the full range of health care services. Specialties include cardiac care from screening to heart surgery and transplantation, cancer care, emergency medicine, pediatrics and maternal-fetal medicine.
Outset is a pioneering medical technology company that always puts the patient before the machine. Our human-centered model is designed to dramatically improve not only the care experience – for patients, families, providers and physicians alike – but also cost-efficiencies for providers. And to achieve this goal, we brought together the most dedicated, creative minds from dialysis with the most dedicated, creative minds from other healthcare fields, in the belief that cross-fertilization – along with hard work – is the surest path to invention. Because we believe a dialysis machine should be as easy to use as an everyday consumer product, Tablo was designed with simplicity in mind. One example is Tablo`s touchscreen display, which offers step-by-step pictures and conversational instructions that make it hard to mess up no matter how new a patient, or caregiver, may be to dialysis. And with simplicity comes speed. We`ve set out to give people their time back. Tablo dramatically reduces the time involved in setting up and managing dialysis. There is simply less to do and less to learn.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.
Helping people experience healthier lives by connecting them to the care, support, and community they need.